EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MRI-Based Model for Personalizing Neoadjuvant Treatment in Breast Cancer

Wen Li iD, Natsuko Onishi iD, Jessica E Gibbs iD, Lisa J Wilmes, Nu N Le, Pouya Metanat, Elissa R Price, Bonnie N Joe iD, John Kornak, Christina Yau, Denise M Wolf, Mark Jesus M Magbanua iD und 5 weitere

Tomography · 27.02.2025 · 11 (3) · 26

DOI: 10.3390/tomography11030026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Tomography, online erschienen am 27.02.2025. Verfasst von Wen Li und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94158, USA. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Breast Neoplasms, Magnetic Resonance Imaging, Precision Medicine. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, NIH/NCI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Functional tumor volume (FTV), measured from dynamic contrast-enhanced MRI, is an imaging biomarker that can predict treatment response in breast cancer patients undergoing neoadjuvant chemotherapy (NAC). The FTV-based predictive model, combined with core biopsy, informed treatment decisions of recommending patients with excellent responses to proceed to surgery early in a large NAC clinical trial.

Methods

In this retrospective study, we constructed models using FTV measurements. We analyzed performance tradeoffs when a probability threshold was used to identify excellent responders through the prediction of pathology complete response (pCR). Individual models were developed within cohorts defined by the hormone receptor and human epidermal growth factor receptor 2 (HR/HER2) subtype.

Results

A total of 814 patients enrolled in the I-SPY 2 trial between 2010 and 2016 were included with a mean age of 49 years (range: 24 to 77). Among these patients, 289 (36%) achieved pCR. The area under the ROC curve (AUC) ranged from 0.68 to 0.74 for individual HR/HER2 subtypes. When probability thresholds were chosen based on minimum positive predictive value (PPV) levels of 50%, 70%, and 90%, the PPV-sensitivity tradeoff varied among subtypes. The highest sensitivities (100%, 87%, 45%) were found in the HR−/HER2+ sub-cohort for probability thresholds of 0, 0.62, and 0.72; followed by the triple-negative sub-cohort (98%, 52%, 4%) at thresholds of 0.13, 0.58, and 0.67; and HR+/HER2+ (78%, 16%, 8%) at thresholds of 0.34, 0.57, and 0.60. The lowest sensitivities (20%, 0%, 0%) occurred in the HR+/HER2− sub-cohort.

Conclusions

Predictive models developed using imaging biomarkers, alongside clinically validated probability thresholds, can be incorporated into decision-making for precision oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyBreast NeoplasmsMagnetic Resonance ImagingPrecision MedicineHumansFemaleMiddle AgedRetrospective StudiesAdultAgedTumor BurdenErb-b2 Receptor Tyrosine KinasesYoung AdultPredictive Value of TestsBreastROC Curve

Stichwörter der Autor:innen

breast cancerdynamic contrast-enhanced MRIfunctional tumor volumeneoadjuvant chemotherapypathologic complete responsetherapy decision

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, human

Autor:innen und Institutionen

  • Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94158, USA.
  • Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94158, USA.
  • Department of Surgery, University of California, San Francisco, CA 94158, USA.
  • Department of Laboratory Medicine, University of California, San Francisco, CA 94158, USA.
  • I-SPY 2 Advocacy Group, San Francisco, CA 94158, USA.
  • Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

ORCID-Profile: Wen Li, Natsuko Onishi, Jessica E Gibbs, Bonnie N Joe, Mark Jesus M Magbanua, Laura J Esserman

Förderung

  • NCI NIH HHS
  • NIH HHS
  • NIH/NCI

Zitieren

APA

Li, W., Onishi, N., Gibbs, J. E., Wilmes, L. J., Le, N. N., Metanat, P., Price, E. R., Joe, B. N., Kornak, J., Yau, C., Wolf, D. M., Magbanua, M. J. M., LeStage, B., van 't Veer, L. J., DeMichele, A. M., Esserman, L. J., & Hylton, N. M. (2025). MRI-Based Model for Personalizing Neoadjuvant Treatment in Breast Cancer. Tomography, 11(3), 26. https://doi.org/10.3390/tomography11030026

Vancouver

Li W, Onishi N, Gibbs JE, Wilmes LJ, Le NN, Metanat P, et al. MRI-Based Model for Personalizing Neoadjuvant Treatment in Breast Cancer. Tomography. 2025;11(3):26. doi:10.3390/tomography11030026

BibTeX
@article{Li2025,
  author = {Li, Wen and Onishi, Natsuko and Gibbs, Jessica E and Wilmes, Lisa J and Le, Nu N and Metanat, Pouya and Price, Elissa R and Joe, Bonnie N and Kornak, John and Yau, Christina and Wolf, Denise M and Magbanua, Mark Jesus M and LeStage, Barbara and van 't Veer, Laura J and DeMichele, Angela M and Esserman, Laura J and Hylton, Nola M},
  title = {MRI-Based Model for Personalizing Neoadjuvant Treatment in Breast Cancer},
  journal = {Tomography},
  year = {2025},
  volume = {11},
  number = {3},
  pages = {26},
  doi = {10.3390/tomography11030026}
}
Kostenlos starten →